Cyclacel Pharmaceuticals, Inc.
CYCC
$0.2452
-$0.0238-8.85%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -37.50% | -98.93% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.50% | -98.93% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -37.50% | -98.93% | -- | -- | -- |
| SG&A Expenses | -23.88% | 3.17% | -3.72% | -12.60% | -20.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -68.12% | -42.11% | -40.10% | -39.05% | 6.09% |
| Operating Income | 68.20% | 38.54% | 40.50% | 39.40% | -5.85% |
| Income Before Tax | 67.66% | 39.19% | 39.64% | 36.74% | -9.66% |
| Income Tax Expenses | 68.56% | 29.69% | -2.58% | 73.31% | 34.12% |
| Earnings from Continuing Operations | 67.56% | 40.22% | 49.24% | 28.95% | -18.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.56% | 40.22% | 49.24% | 28.95% | -18.37% |
| EBIT | 68.20% | 38.54% | 40.50% | 39.40% | -5.85% |
| EBITDA | 68.18% | 38.49% | 40.46% | 39.44% | -5.85% |
| EPS Basic | 87.40% | 72.54% | 67.58% | 30.27% | -15.12% |
| Normalized Basic EPS | 87.33% | 71.81% | 61.12% | 38.08% | -6.81% |
| EPS Diluted | 87.40% | 72.54% | 67.58% | 30.27% | -15.12% |
| Normalized Diluted EPS | 87.33% | 71.81% | 61.12% | 38.08% | -6.81% |
| Average Basic Shares Outstanding | 155.33% | 115.73% | 55.26% | 2.17% | 2.67% |
| Average Diluted Shares Outstanding | 155.33% | 115.73% | 55.26% | 2.17% | 2.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -0.41% | 0.16% |
